FY2026 · ended Jun 30, 2026 · Revenue $1.22B, -0.4% YoY · Filed Aug 24, 2026
Bio-Techne Corp (TECH) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $1.2 billion and net income of $181.9 million. Free cash flow was $263.2 million. As of Jun 30, 2026 it held $264.7 million in cash and investments and $289.1 million in total debt.
Revenue
$1.22B
-0.4% vs prior year
Net income
$181.86M
+147.8% vs prior year
Operating cash flow
$292.07M
+1.6% vs prior year
Free cash flow
$263.22M
+2.6% vs prior year
EPS
$1.16
+152.2% vs prior year
Dividend per share
$0.32
+0.0% vs prior year
Shares outstanding
157.06M
+0.2% vs prior year
Net cash
$-24.38M
FY 2026
Operating margin
20.7%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B |
| Operating income | $251.9M | $102.3M | $206.7M | $298.9M | $296.6M |
| Net income | $181.9M | $73.4M | $168.1M | $285.4M | $263.1M |
| Diluted EPS | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 |
| Operating cash flow | $292.1M | $287.6M | $299.0M | $254.4M | $325.3M |
| Free cash flow | $263.2M | $256.6M | $236.1M | $216.1M | $280.4M |
| Total assets | $2.6B | $2.6B | $2.7B | $2.6B | $2.3B |
| Stockholders' equity | $2.1B | — | $2.1B | $2.0B | $1.7B |
| Cash and investments | $264.7M | $162.2M | $152.9M | $204.3M | $247.0M |
| Total debt | $289.1M | $444.1M | $419.5M | $455.0M | $82.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-K/A | Amended annual report | Oct 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-K | Annual report | Aug 24, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
All 1001 Bio-Techne Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.